indapamide serum binding was increased in patients with inflammatory syndrome ( 82.2 +/- 3.4 % , p less than .001 ) , decreased in patients with hepatic insufficiency ( 72.3 +/- 5.9 % , p less than .001 ) and unchanged in patients with renal insufficiency ( 77.7 +/- 2.8 % ) as compared with controls ( 78.2 +/- 3.1 % ) .
C0021186
indapamide
C0035078
renal insufficiency